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Silver–Russell syndrome (SRS, OMIM #180860, also 
known as Russell–Silver syndrome, RSS) is a rare, but 
well-recognized, condition associated with prenatal 
and postnatal growth retardation. The syndrome was 
first described by Silver et al.1 and Russell2, who inde-
pendently described a subset of children with low birth 
weight, postnatal short stature, characteristic facial fea-
tures and body asymmetry. Almost all patients with 
SRS are born small for gestational age (SGA; BOX 1). 
The aetiology of intrauterine growth retardation and 
SGA is extremely heterogeneous. Children with SRS 
can be distinguished from those with idiopathic intra-
uterine growth retardation or SGA and postnatal 
growth failure by the presence of other characteristic 
features, including relative macrocephaly (defined as a 
head circumference at birth ≥1.5 SD score (SDS) above 
birth weight and/or length SDS), prominent forehead, 
body asymmetry and feeding difficulties3–6.
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Abstract | This Consensus Statement summarizes recommendations for clinical diagnosis, 
investigation and management of patients with Silver–Russell syndrome (SRS), an imprinting 
disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists 
between the care of individuals born small for gestational age and those with SRS. However, many 
specific management issues exist and evidence from controlled trials remains limited. SRS is 
primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical 
diagnosis and defines the subtype. A ‘normal’ result from a molecular test does not exclude the 
diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary 
approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal 
problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial 
challenges. An early emphasis on adequate nutritional status is important, with awareness that 
rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The 
benefits of treating patients with SRS with growth hormone include improved body composition, 
motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians 
should be aware of possible premature adrenarche, fairly early and rapid central puberty and 
insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay 
progression of central puberty and preserve adult height potential. Long-term follow up is essential 
to determine the natural history and optimal management in adulthood.
Correspondence to E.L.W.  
and I. N.  
e.wakeling@nhs.net;  
irene.netchine@aphp.fr
doi:10.1038/nrendo.2016.138
Published online 2 Sep 2016
NATURE REVIEWS | ENDOCRINOLOGY  ADVANCE ONLINE PUBLICATION | 1
CONSENSUS
STATEMENT
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Globally, estimates of the incidence of SRS range from 
1:30,000 to 1:100,000 (REF. 7). In 2015, a study in Estonia8 
estimated an incidence of 1:70,000; however, only molec-
ularly confirmed cases were included, which could have 
resulted in underdiagnosis. Overall, SRS is probably more 
common than some previous estimates have suggested, 
but the exact incidence remains unknown.
An underlying molecular cause can currently be iden-
tified in around 60% of patients clinically diagnosed with 
SRS4. The most common underlying mechanisms are loss 
of methylation on chromosome 11p15 (11p15 LOM; seen 
in 30–60% of patients) and maternal uniparental dis-
omy for chromosome 7 (upd(7)mat; seen in ~5–10% of 
patients)4,9,10. However, the molecular aetiology remains 
unknown in a substantial proportion of patients.
Although considerable overlap exists in the clinical 
care of individuals born SGA and those with SRS, many 
management issues are specific to SRS. These include 
notable feeding difficulties, severe postnatal growth fail-
ure with no catch-up, recurrent hypoglycaemia, prema-
ture adrenarche, fairly early and rapid central puberty, 
insulin resistance and body asymmetry. Identification 
of the molecular cause in many patients has also raised 
questions about the management of individual molecu-
lar subtypes of SRS. As evidence from controlled trials is 
limited, a consensus meeting was organized to develop 
guidelines for the diagnosis and management of patients 
with SRS.
This Consensus Statement was produced on behalf 
of the COST Action BM1208 (European Network for 
Human Congenital Imprinting Disorders, http://www.
imprinting-disorders.eu), European Society of Pediatric 
Endocrinology (ESPE), Pediatric Endocrine Society 
(PES), Asian Pacific Pediatric Endocrine Society (APPES) 
and Sociedad Latino-Americana de Endocrinología 
Pediátrica (SLEP).
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Methods
41 task force members from 16 countries, chosen for 
their publication record and expertise in SRS, collabo-
rated to develop this consensus statement. They included 
paediatric endocrinologists, clinical geneticists, molecu-
lar geneticists, a gastroenterologist and five non-voting 
representatives from a parent support group. Participants 
included representatives nominated by the council and 
clinical practice committees from four international 
paediatric endocrine societies. All participants signed 
a conflict of interest declaration, and the consensus was 
supported by academic funding, without pharmaceuti-
cal support. A Delphi-like consensus methodology was 
adopted11. A comprehensive literature search was con-
ducted using PubMed and the search terms “Silver Russell 
syndrome” and “Russell Silver syndrome”. Additional 
relevant articles on SGA, differential diagnoses and 
growth hormone (GH) were also identified by PubMed 
searches when supplementary information was neces-
sary. A comprehensive review of >600 articles formed 
the basis of discussion by three working groups. These 
groups focused on clinical diagnosis (working group 1: 
E.L.W., J.S., K.H.C., M.E., R.P.D., P.G.M., T.O., E.S., M.T. 
and I.K.T.), molecular testing (working group 2: F.B., J.B., 
K.G., M.K., D.M., G.E.M., S.R., Z.T., T.E. and D.J.G.M) 
and clinical management (working group 3: O.L.-S., 
S.M.O’C., J.H.D., A.P.M.C., B.D., E.G., A.G., A.C.S.H.-K., 
A.A.J., A.L., M.M., K.M., I.O.P., G.B., M.D.H. and I.N.), 
with 10, 10 and 16 members, respectively. Preparations 
for the consensus took place over 10 months, including 
two preparatory meetings and regular teleconference dis-
cussions between the working group members. At the 
final consensus meeting, propositions and recommen-
dations were considered by participants and discussed 
in plenary sessions, enabling reformulation of the rec-
ommendations if necessary. Where published data were 
unavailable or insufficient, experts’ clinical experiences 
and opinions were considered. Finally, all experts voted 
on the recommendations of each working group using 
the following system:
A. Evidence or general agreement allow full agree-
ment with the recommendation
B. Evidence or general agreement are in favour of 
the recommendation
C. Evidence or general agreement are weak for the 
recommendation
D. There is not enough evidence or general agreement 
to agree with the recommendation
Depending on the proportion of votes received, the 
strength of the recommendation was recorded as follows:
+ 26–49% of the votes
++ 50–69% of the votes
+++ ≥70% of the votes
Clinical diagnosis
SRS is currently a clinical diagnosis based on a combina-
tion of characteristic features. Molecular testing can con-
firm the diagnosis in around 60% of patients4. Molecular 
testing enables stratification of patients with SRS into 
subgroups, which can lead to more tailored manage-
ment. However, molecular investigations are negative 
in a notable proportion of patients with characteristic 
clinical features of SRS. For these patients, an estab-
lished clinical diagnosis enables access to appropriate 
support groups, treatment (including GH) and further 
research into the underlying incidence, natural history 
and aetiology of the SRS phenotype.
However, the diagnosis of SRS can be difficult, as 
the condition varies widely in severity among affected 
individuals and many of its features are nonspecific4–6. 
Until now, no consensus has been reached on the clini-
cal definition of SRS. Historically, this lack of consensus 
has probably led to underdiagnosis and overdiagnosis, 
particularly by clinicians unfamiliar with SRS.
Several clinical scoring systems for SRS have been 
proposed, which reflects the challenge in reaching a con-
fident diagnosis4,5,12–15. All the systems use similar criteria, 
but vary in the number and definition of diagnostic fea-
tures required for diagnosis. The relative sensitivity and 
specificity of these scoring systems have been compared 
in patients with confirmed molecular diagnoses14,15.
Netchine–Harbison clinical scoring system
The Netchine–Harbison clinical scoring system (NH-CSS; 
TABLE 1), which was proposed by Azzi and colleagues in 
2015,15 is the only scoring system for the diagnosis of SRS 
that was developed using prospective data. Four of the six 
criteria are objective; protruding forehead and feeding dif-
ficulties remain subjective, but clear clinical definitions are 
given. Using the same cohort, the NH-CSS proved more 
sensitive (98%) than previous systems4,14. The NH-CSS 
also had the highest negative predictive value (89%), 
which gives a high degree of confidence that patients who 
have less than four of the six clinical criteria for diagnosis 
are truly unaffected by SRS. The system is easy to use in a 
busy clinical setting. The NH-CSS is also flexible enough 
to use even if data are incomplete, which is important as 
the diagnosis is often made in infancy, before information 
about postnatal growth and BMI is available.
Box 1 | Definitions
Small for gestational age (SGA)
Weight and/or length less than −2 SDS for gestational 
age at birth, based on accurate anthropometry at birth 
(including weight, length and head circumference) and 
reference data from a relevant population106.
Intrauterine growth retardation
Also known as intrauterine growth restriction, this 
diagnosis is based on at least two ultrasonography 
measurements at least 2 weeks apart, with fetal weight 
below the 10th percentile for gestational age. 
Intrauterine growth retardation might or might not 
result in a baby born SGA161.
Silver–Russell syndrome (SRS)
A distinct syndromic growth disorder in which prenatal 
and postnatal growth failure are associated with other 
characteristic features, including relative macrocephaly 
at birth, protruding forehead in early life, body 
asymmetry and substantial feeding difficulties. Almost all 
children with SRS are born SGA. Postnatal catch-up 
growth is not seen in the majority of children with SRS.
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Similarly to other clinical scoring systems, the NH-CSS 
has a low specificity (36%)15, which could result in false 
positive results when the diagnosis is just based on clinical 
findings. Relative macrocephaly at birth (defined as a head 
circumference at birth ≥1.5 SDS above birth weight and/or 
length SDS) and protruding forehead are the two features 
in the NH-CSS that best distinguish SRS from non-SRS 
SGA (see Supplementary information S1 (table))4,15–18. To 
maintain confidence in the clinical diagnosis if all molec-
ular testing is normal, we recommend that only patients 
scoring at least four of six criteria, including both promi-
nent forehead and relative macrocephaly, should be diag-
nosed as ‘clinical SRS’ (previously known as ‘idiopathic 
SRS’); see the flow diagram for investigation and diagnosis 
of SRS (FIG. 1).
Diagnosis in late childhood or adulthood
All scoring systems for SRS have been developed and 
validated in paediatric cohorts. However, an increasing 
number of adults with a historical diagnosis of SRS are 
being seen by clinicians, particularly regarding their 
concerns about passing the condition on to their off-
spring (personal experience of working groups 1 and 
3). In these patients, a clinical diagnosis is frequently 
challenged by lack of early growth data. An attempt 
should be made to obtain photographs of the individual 
aged 1–3 years, especially of the face in profile, as well as 
measurements at birth and in the first 2 years. No cur-
rent evidence exists to support an alternative approach 
to diagnosis in adults.
Additional clinical features
In addition to the clinical features in the NH-CSS, several 
others are recognized in association with SRS, as shown in 
TABLE 2 and Supplementary information S1 (table). These 
characteristics are not specific to SRS, and might be pres-
ent in children born SGA who do not have SRS, but at a 
lower frequency than in patients with SRS. However, a few 
features occur at a much higher rate in children with SRS 
than in those with SGA4,15,16. These features include low 
muscle mass, crowded or irregular teeth, micrognathia, 
down-turned mouth, clinodactyly and excessive sweating.
1  Recommendations
1.1 SRS should remain primarily a clinical diagnosis. 
Molecular testing is useful for the confirmation and 
stratification of diagnosis in SRS. Lack of a positive 
molecular result does not exclude the diagnosis of 
SRS. (A+++)
1.2 The flow chart (FIG. 1), based on the NH-CSS, should 
be adopted for the investigation and diagnosis of 
SRS. (A++)
1.3 In children aged <2 years, adolescents and adults, 
a reduced threshold for molecular testing might be 
required due to missing data. (A++)
Molecular diagnosis
Investigation and diagnosis
A positive molecular test result provides useful confir-
mation of the clinical diagnosis (FIG. 1). This result also 
enables stratification into a specific molecular subgroup 
that, in turn, can help guide appropriate management. 
However, many patients are referred for molecular testing 
with few, or atypical, features of SRS, which leads to low 
diagnostic yields and incurs unnecessary expense19. We, 
therefore, recommend the use of the flow chart in FIG. 1 
to aid in the investigation and diagnosis of SRS.
Some patients, particularly those with upd(7)mat, 
have fewer typical clinical features of SRS than patients 
with 11p15 LOM4,5,13,16,20,21. In the cohort reported by Azzi 
and co-workers15, one of the nine patients scoring three 
of six criteria (and therefore predicted ‘unlikely to have 
SRS’) had upd(7)mat. The threshold recommended in 
FIG. 1 for molecular testing (≥3 of six criteria) is, therefore, 
lower than that needed for a clinical diagnosis of SRS (≥4 
of six criteria).
Conversely, in the same cohort, no positive molec-
ular diagnoses were made in patients scoring less than 
three of six criteria15. Other studies have also excluded 
11p15 LOM and upd(7)mat in patients born SGA with 
postnatal growth retardation but without additional 
features of SRS4,10,22. We, therefore, do not recommend 
testing for SRS in patients scoring less than three of six 
criteria. Of note, a small number of patients with body 
asymmetry have been reported to have 11p15 LOM 
Table 1 | Netchine–Harbison clinical scoring system
Clinical criteria Definition
SGA (birth weight and/or birth length) ≤−2 SDS for gestational age
Postnatal growth failure Height at 24 ± 1 months ≤−2 SDS or height ≤−2 SDS below mid-parental 
target height
Relative macrocephaly at birth Head circumference at birth ≥1.5 SDS above birth weight and/or length SDS
Protruding forehead* Forehead projecting beyond the facial plane on a side view as a toddler 
(1–3 years)
Body asymmetry LLD of ≥0.5 cm or arm asymmetry or LLD <0.5 cm with at least two other 
asymmetrical body parts (one non-face)
Feeding difficulties and/or low BMI BMI ≤−2 SDS at 24 months or current use of a feeding tube or 
cyproheptadine for appetite stimulation
Clinical diagnosis is considered if a patient scores at least four of six from these criteria. If all molecular tests are normal and 
differential diagnoses have been ruled out, patients scoring at least four of six criteria, including both prominent forehead and relative 
macrocephaly should be diagnosed as clinical Silver–Russell syndrome. *Protruding forehead is equivalent to ‘prominent forehead’ 
(REF. 164). LLD, leg length discrepancy; SDS, SD score; SGA, small for gestational age.
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Figure 1 | Flow chart for investigation and diagnosis of SRS. Diagnostic questions are in blue boxes; recommended 
molecular tests are in beige boxes. Pink boxes: diagnosis not confirmed; green boxes: diagnosis of SRS confirmed. 
*Studies have excluded 11p15 LOM and upd(7)mat in patients with intrauterine growth retardation and postnatal growth 
retardation alone; some patients, particularly those with upd(7)mat or children under 2 years, score 3/6 (see text for 
details). ‡Arrange CNV analysis before other investigations if patient has notable unexplained global developmental delay 
and/or intellectual disability and/or relative microcephaly. §Insufficient evidence at present to determine relationship to 
SRS, with the exception of tissue mosaicism for 11p15 LOM. ||Unless evidence of catch-up growth by 2 years. ¶Previously 
known as idiopathic SRS. CNV, copy number variant; LOM, loss of methylation; NH-CSS, Netchine-Harbison clinical 
scoring system; SRS, Silver–Russell syndrome.
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Does the patient meet the clinical criteria
for diagnosis of SRS (NH-CSS)?Yes 
(score ≥4/6)
No 
(score ≤3/6)
Diagnosis not conﬁrmedMolecular testing for 
11p15 and upd(7)mat‡
Positive
Positive
Negative
Negative
Molecular diagnosis 
conﬁrmed — the 
patient has SRS
Does the patient have 
relative microcephaly?
No
No
No
Yes
Yes
Yes||
Diagnosis not conﬁrmed
Consider diﬀerential
diagnosis (Table 3)
Molecular testing 
as per diﬀerential 
diagnosis
Consider additional 
molecular testing:
• CNV and/or 14q32 analysis 
    followed by upd(16)mat, 
    upd(20)mat or CDKN1C 
    or IGF2 mutation analysis
• Alternative tissue analysis
Alternative molecular 
diagnosis§
What is the NH-CSS
score?
4/6≥5/6 3/6
Does the patient have
relative macrocephaly
and protruding forehead?
Clinical SRS¶ Diagnosis not conﬁrmed
Consider diﬀerential
diagnosis (Table 4)
Are the clinical features 
consistent with a 
diﬀerential diagnosis?
Diagnostic questions
Recommended molecular tests
Diagnosis not conﬁrmed
Diagnosis of SRS conﬁrmed
Or
No, but continued  
clinical suspicion 
(score 3/6)*
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without associated growth retardation, probably due to 
tissue mosaicism20,21,23. These patients would score fewer 
than three of six criteria, which is insufficient to justify a 
clinical diagnosis of SRS in these patients.
Chromosome 11p15
Both SRS and the overgrowth condition Beckwith–
Wiedemann syndrome are associated with molecular 
abnormalities of chromosome 11p15.5, which contains 
two imprinted domains (FIG. 2). Imprinting of the telo-
meric domain, which is strongly implicated in SRS24,25, is 
controlled by the paternally methylated imprinting con-
trol region H19/IGF2 IG-DMR (H19/IGF2 intergenic 
differentially methylated region, previously known as 
IC1, ICR1 and H19 DMR). The centromeric domain 
contains the maternally expressed growth repressor 
CDKN1C; the imprinting of this gene is controlled by 
the maternally methylated imprinting control region 
KCNQ1OT1 TSS-DMR (previously known as IC2, 
ICR2, LIT1 or KvDMR1). FIGURE 3 summarises the more 
common molecular changes at chromosome 11p15 
associated with SRS. Hypomethylation of the H19/IGF2 
IG-DMR results in reduced paternal IGF2 expression 
and increased maternal H19 expression, which leads 
to growth restriction9. Numerous copy number vari-
ants (CNVs) involving the 11p15.5 region have been 
reported; the phenotype is dependent on CNV size, 
location and parental origin24,26 (see Supplementary 
information S2 (table)).
Molecular testing must robustly and accurately meas-
ure DNA methylation of CpG dinucleotides at H19/IGF2 
IG-DMR27. Assays involve either bisulfite analysis28–30 
or enzymatic methods, such as methylation-specific 
multiplex ligation-mediated PCR amplification 
(MS-MLPA) or Southern blotting9,31. The most common 
test in diagnostic use is MS-MLPA, which is economical 
on DNA, cost-effective and enables parallel analysis of 
copy number and DNA methylation31,32. Hypomethylation 
of H19/IGF2 IG-DMR is frequently incomplete and 
low levels of hypomethylation might elude detection. 
Methylation patterns might vary between different tis-
sues and cells (leucocytes, samples from a buccal swab and 
skin fibroblasts)21,33,34 and could explain cases of a negative 
molecular diagnosis using a blood sample.
Although copy number change can be detected 
by MS-MLPA, additional array analysis is useful for 
characterizing the size and gene content of any CNV 
identified.
Chromosome 7
Of individuals with SRS, ≤10% have upd(7)mat35,36. The 
SRS phenotype of upd(7)mat is thought to result from 
altered expression of an imprinted growth-regulatory 
gene (or genes)37. In addition, the duplication of pre-ex-
isting pathogenic mutations by isodisomy can lead to the 
clinical expression of recessive disorders (such as cystic 
fibrosis) in patients with upd(7)mat38–40.
Candidate SRS regions have been suggested through 
identification of patients with segmental upd(7)mat or 
CNVs (see Supplementary information S3 (table)); the 
primary candidate SRS genes on chromosome 7 are 
currently GRB10 (7p12.1) and MEST (7q32)41–48.
Microsatellite analysis was the first diagnostic test 
for upd(7)mat35,36; however, this analysis cannot detect 
imprinting defects (epimutations) and requires DNA 
from at least one parent. DNA methylation analysis, 
including at least the imprinting control regions GRB10 
alt-TSS-DMR and MEST alt-TSS-DMR, can identify 
upd(7)mat, epimutations, CNVs and segmental or 
whole-chromosome variations. DNA methylation anal-
ysis, for example by MS-MLPA, is economical on DNA, 
cost-effective and compatible with parallel analysis of 
11p15 (REFS 30,49,50).
Additional testing
If testing of both 11p15 and chromosome 7 is negative, 
additional molecular testing can be considered.
CNVs. Over 30 different pathogenic CNVs have been 
described in patients with suspected SRS15,51–53. Patients 
with these CNVs usually have more severe developmen-
tal delay and/or intellectual disability than is typically 
seen in SRS52,53. Some patients fulfil the NH-CSS for 
diagnosis; others either do not meet the NH-CSS cri-
teria, or insufficient data are given to use the criteria 
for their assessment. Although features of SRS can be 
present in individuals with a pathogenic CNV, clinical 
diagnosis of SRS is not helpful in these cases and man-
agement needs to be tailored specifically to the pheno-
typic consequences of the individual CNV.
While either array comparative genomic hybridiza-
tion or single nucleotide polymorphism array can be used 
to detect CNVs, single nucleotide polymorphism array 
can also detect regions of segmental isodisomy54.
Table 2 | Additional clinical features of Silver–Russell syndrome
Clinical feature Frequency %  
(total no. patients)
Refs
Triangular face 94 (164) 16–18
Fifth finger clinodactyly 75 (319) 4,15–18,20
Shoulder dimples 66 (61) 15
Micrognathia 62 (115) 16,18,20
Low muscle mass 56 (103) 15,16
Excessive sweating 54 (106) 16,20
Low-set and/or posteriorly rotated ears 49 (266) 15–17,20
Down-turned mouth 48 (176) 15,16,18,20
High pitched or squeaky voice 45 (26) 16
Prominent heels 44 (61) 15
Delayed closure of fontanelle 43 (47) 18,20
Male genital abnormalities 40 (85) 15,16,18,20
Speech delay 40 (189) 16,17,20
Irregular or crowded teeth 37 (195) 16–18,20
Motor delay 37 (254) 4,16–18,20
Syndactyly of toes 30 (264) 15–17,20
Hypoglycaemia 22 (103) 4,20
Scoliosis and/or kyphosis 18 (227) 16,20,147
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Chromosome 14q32 abnormalities. Molecular abnor-
malities at the paternally methylated imprinted locus 
on chromosome 14q32 include upd(14)mat, paternal 
microdeletions and hypomethylation of the DLK1/GTL2 
IG-DMR (also referred to as MEG3-DMR, 14q32 DMR 
or IG-DMR). These result in Temple syndrome, which 
has clinical overlap with SRS55,56, including being born 
SGA, postnatal growth retardation, hypotonia, delay in 
the development of motor skills and early puberty55.
In cohorts of patients with SRS, a small number of 
patients have been found to have Temple syndrome: 1 
of 127 patients57, 2 of 85 patients56 and 1 of 26 patients15. 
However, the true incidence of 14q32 abnormalities 
in patients meeting the NH-CSS criteria for diagnosis 
remains unknown.
upd(20)mat and upd(16)mat. Patients with both 
upd(20)mat and upd(16)mat have occasionally been 
detected among cohorts of patients investigated for pre-
natal and postnatal growth failure or SRS15,57,58. However, 
in a study published in 2015, none of eight patients with 
upd(20)mat had relative macrocephaly or asymmetry59, 
two important criteria of the NH-CSS, which means that 
these patients might have eluded formal clinical diagnosis 
of SRS.
CDKN1C and IGF2 mutations. CDKN1C and IGF2 are 
the coding genes on chromosome 11p15 that are respon-
sible for the growth anomalies in SRS and Beckwith–
Wiedemann syndrome. Maternally transmitted SRS was 
described in a four-generation family with a CDKN1C 
gain-of-function mutation60, and paternally transmitted 
SRS in a family with an IGF2 loss-of-function mutation61. 
However, no additional mutations have been reported to 
date in sporadic or familial cases of SRS60,62,63. Sequence 
analysis of either gene might be considered, particularly 
in familial cases of SRS where the inheritance pattern is 
consistent; however, coding variants in these genes are 
rare60,62,63.
Multi-locus imprinting disturbance. A significant pro-
portion (15–38%) of individuals with 11p15 LOM have 
multi-locus imprinting disturbance (MLID)33,57,64–66. 
High-density methylation arrays have revealed methyl-
ation changes involving both (maternally and paternally) 
imprinted and non-imprinted loci67,68. However, despite 
welcome advances in genome-wide methylation screen-
ing67,69,70, standardization is required to ensure accurate 
description of MLID and comparison between cohorts.
The effect of MLID on clinical phenotype remains 
unclear. No difference in growth parameters was found 
at birth or at 2 years of age between patients with 11p15 
LOM with and without MLID64. Although develop-
mental delay and congenital anomalies were reported 
in patients with MLID, this finding might have been 
affected by ascertainment bias57.
In principle, MLID might be caused by trans-acting 
genetic mutations that affect the acquisition or mainte-
nance of imprints, but in practice, very few have been 
identified71,72.
Figure 2 | The imprinted domains of chromosome 11p15 that are 
implicated in Silver–Russell syndrome. a | Representation of the 11p15 
region, showing both centromeric and telomeric domains. Only the 
imprinted genes that are implicated in the pathophysiology of Silver–
Russell syndrome are represented. Blue boxes indicate paternally 
expressed genes (the growth promoter IGF2 and the long noncoding RNA 
(lncRNA) KCNQ1OT1). Red boxes indicate maternally expressed genes (the 
growth inhibitor CDKN1C, the ion channel KCNQ1 and the noncoding 
RNA H19). Ovals indicate differentially methylated regions (DMRs). Dark 
grey ovals indicate methylated DMRs. Beige ovals indicate unmethylated 
DMRs. b | Structure of the H19/IGF2 IG-DMR (intergenic differentially 
methylated region). This DMR contains short repetitive blocks of sequence 
and harbours seven binding sites for the zinc finger protein CTCF (green 
circles). Multiple enhancer elements (grey hexagons) distal to H19 are 
shared between H19 and IGF2, and are able to increase expression of 
either. Binding of CTCF to the unmethylated maternal DMR blocks 
interactions between the IGF2 promoter and enhancers downstream of 
H19, which results in maternal H19 expression. Conversely, methylation of 
ICR1 on the paternal allele prevents CTCF binding, enabling interaction 
between the IGF2 promoter and distal enhancers, and thus paternal IGF2 
expression162,163. Beige triangles indicate unmethylated CTCF binding sites. 
Dark grey triangles indicate methylated CTCF binding sites.
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Overall, the effect of MLID on clinical phenotype and 
its relevance for genetic counselling remain uncertain. 
Further information is needed before recommending 
testing for MLID outside the research setting.
2  Recommendations
2.1 Molecular genetic testing should be performed 
by a health professional experienced in the field 
of imprinting disorders. Consistent and logical 
nomenclature should be adopted in publications 
and in test reporting. (A+++)
2.2 First-line molecular testing should include DNA 
methylation analysis of the H19/IGF2 IG-DMR and 
KCNQ1OT1 TSS-DMR. (A+++)
2.3 First-line molecular testing should include analysis 
of DNA methylation at the GRB10 alt-TSS-DMR 
and the MEST alt-TSS-DMR. (A+++)
2.4 In case of a positive test result at either 11p15 or 
chromosome 7, discrimination between epimuta-
tion, CNV and upd should be considered to estimate 
recurrence risk. (A+++)
2.5 After exclusion of changes in 11p15 and chromo-
some 7, a clinical decision should be sought about the 
direction of further testing. Depending on the clinical 
features and family history of the patient, further test-
ing might include CNV analysis and DNA methyl-
ation analysis at chromosome 14q32. Testing might 
also be considered for very rare molecular anomalies, 
including upd(20)mat, upd(16)mat and mutations 
in CDKN1C and IGF2, as well as analysis of further 
tissues to detect somatic mosaicism. (A++)
2.6 When an underlying pathogenic CNV is identified, 
the diagnosis should focus on this finding, even if 
features of SRS are present. (A+)
(Epi)genotype–phenotype correlation
The frequency of individual features in specific SRS sub-
groups (11p15 LOM, upd(7)mat and clinical SRS) and 
patients with SGA but not SRS, where data are available, 
are shown in Supplementary information S1 (table). 
Genotype–phenotype studies of patients with SRS indi-
cate considerable overlap in clinical phenotype between 
(epi)genotypes, and these are generally clinically indis-
tinguishable. However, some features are more common 
in particular molecular subgroups4,13,15–17,20,73.
Patients with 11p15 LOM tend to have a lower birth 
length and weight, more frequent body asymmetry and 
more frequent congenital anomalies than patients with 
Figure 3 | Mutations and epimutations of the imprinted region at chromosome 11p15 associated with Silver–
Russell syndrome. The structure of the 11p15 region is represented as in FIG. 2. Paternal hypomethylation of H19/IGF2 
IG-DMR results in loss of paternal IGF2 expression and gain of maternal H19 expression, which leads to a growth 
restriction phenotype9. Less commonly, maternal duplication of the centromeric or both domains results in growth 
retardation due to increased dosage of CDKN1C; however, smaller copy number variants should be classified with 
caution due to the complex regulation of the region27. Rare familial cases have been associated with a maternal CDKN1C 
gain-of-function mutation (green cross)60 or a paternal IGF2 loss-of-function mutation (red cross)61.
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upd(7)mat15,20. Neurocognitive problems are more fre-
quent in patients with upd(7)mat than in those with 
11p15 LOM or clinical SRS15,16,20 (see later section on 
neurocognitive problems).
Patients with 11p15 duplication encompassing H19/
IGF2 IG-DMR and KCNQ1OT1 TSS-DMR have an SRS 
phenotype, but usually without asymmetry and with an 
increased likelihood of developmental delay53. Of 15 
patients reported to have a 11p15 duplication encompass-
ing H19/IGF2 IG-DMR and KCNQ1OT1 TSS-DMR, 
four were noted to have hearing loss74.
Differential diagnosis
The differential diagnosis of children with short stat-
ure of prenatal onset includes many syndromic diag-
noses and chromosomal rearrangements75 (TABLES 3,4). 
Particular features should prompt consideration of diag-
noses other than SRS. These include relative microceph-
aly (head circumference SDS below height and weight 
SDS), notable global developmental delay or intellectual 
disability (without a related explanation such as docu-
mented hypoglycaemia), absence of severe feeding dif-
ficulties and/or the presence of additional congenital 
anomalies, facial dysmorphism or other features atypical 
of SRS. Disproportionate short stature is suggestive of 
skeletal dysplasia. Photosensitive skin rash or recurrent 
bronchopulmonary infections should prompt investiga-
tion for chromosome breakage disorders. As SRS is gen-
erally sporadic, a family history of growth failure and/or 
consanguinity might suggest an alternative underlying 
diagnosis76. The clinical features of the most important 
and/or likely differential diagnoses are summarized in 
TABLES 3,4.
A correct diagnosis can have extremely important 
implications for management. Response to GH treat-
ment, if given, varies depending on the underlying 
syndromic diagnosis. For instance, GH treatment is 
contraindicated in patients with chromosome breakage 
disorders, such as Bloom syndrome, due to the associ-
ated risk of malignancy77. GH treatment in patients with 
SHORT syndrome has been reported to precipitate insu-
lin resistance and subsequent type 2 diabetes mellitus78. 
An incorrect diagnosis of SRS leading to the recommen-
dation of GH treatment could, therefore, have adverse 
consequences in these patients.
Three patients (one with no history of fractures) have 
been reported with clinical features of SRS but a molecu-
lar diagnosis of osteogenesis imperfecta, with a COL1A1 
mutation79,80. Both SRS and osteogenesis imperfecta can 
cause prenatal onset of growth failure, relative macro-
cephaly, large fontanelle, blue sclerae and body asymme-
try. Both diagnoses should, therefore, be considered in 
patients with features overlapping both conditions.
3 Recommendations
3.1 An alternative syndromic diagnosis, and specific 
investigation for this diagnosis, should be particu-
larly considered in patients with any of the fol-
lowing: additional features atypical of SRS, family 
history of growth failure and/or consanguinity. 
(A+++)
3.2 Patients with features of SRS overlapping with oste-
ogenesis imperfecta should have a skeletal survey to 
look for additional evidence for osteogenesis imper-
fecta, with consideration of COL1A1/2 gene testing. 
(A++)
Management
SRS leads to a wide spectrum of abnormal phys-
ical characteristics and functional abnormalities. 
Multidisciplinary follow up and early, specific, inter-
vention are necessary for optimum management of this 
group of patients.
4  Recommendation
4.1 Patients with SRS should receive multidisciplinary 
care in a centre of expertise in SRS in coordination 
with their local centre. The multidisciplinary team 
should be composed of paediatric subspecialists 
such as an endocrinologist (coordinator), gastroen-
terologist, dietician, clinical geneticist, craniofacial 
team, orthopaedic surgeon, neurologist, speech and 
language therapist and psychologist. (A+++)
Early feeding and nutritional support
The typical neonate with SRS has length SDS below 
weight SDS; but after birth, due to poor appetite, feed-
ing difficulties and gastrointestinal problems, weight 
SDS drops below the length SDS4,17,73,81. Over time, pro-
gressive failure to thrive can result in a calorie-related 
length deficit4,15,82.
Feeding difficulties and failure to thrive are consider-
ably more frequent in patients with SRS than in children 
with SGA but not SRS4,17. Failure to thrive in children 
with SRS is probably due to a combination of factors, 
including feeding difficulties (poor appetite, oromo-
tor issues and the resulting low caloric intake) as well 
as functional and structural gastrointestinal problems. 
Digestive problems or malnutrition occur in over 70% of 
patients with SRS82, including severe gastrooesophageal 
reflux in 55%, which often results in persistent vomit-
ing after the age of 1 year. Constipation is also common, 
particularly after age 2 years82. Cyproheptadine used 
as an appetite stimulant improves weight gain in other 
paediatric conditions83,84; however, specific studies of its 
use in SRS are needed before it can be recommended in 
these patients.
The main therapeutic goals for the first 2 years of life 
in patients with SRS are nutritional support, prevention 
of hypoglycaemia and recovery of any calorie-related 
length or height deficit, which should be addressed 
before initiation of GH therapy (see following sections 
on prevention of hypoglycaemia and GH therapy). 
However, careful monitoring is needed, especially dur-
ing nonvolitional feeding, because rapid catch-up weight 
gain in children born SGA has been associated with an 
increased risk of metabolic and cardiovascular disease 
in later life85.
Children with SRS have an abnormal body composi-
tion with low muscle mass, and are typically light for their 
length or height3,15,86,87. From our experience, the target 
for healthy nutritional status is narrow, and is dependent 
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on individual innate muscle mass and even slight over-
nourishment (for example, weight >90% of ideal weight 
for length or height) can rapidly increase relative fat mass. 
Suggested targets for children aged 2–4 years preparing 
for GH therapy are: weight 75–85% of the 50th centile 
weight for length or height and/or BMI 12–14 kg/m2, 
using height measurements on the longer side if notable 
leg length discrepancy is found (see following section on 
GH therapy). A weight below 70% of the ideal weight for 
length or height compromises growth velocity, despite 
GH treatment. For children >4 years old, the optimal tar-
get BMI will depend on their muscle mass. Two groups 
of patients are exceptions to this observation. Firstly, in 
patients with 11p15 LOM who have a very low muscle 
mass and considerable body asymmetry, a lower BMI 
might be adequate (11–12 kg/m2). Secondly, for patients 
with upd(7)mat with near normal muscle mass, a higher 
BMI might be acceptable (14–15 kg/m2).
5  Recommendations
5.1 For nutritional goals in the first years of life, we 
recommend nutritional repletion* with awareness 
of possible hazards of rapid postnatal catch-up 
leading to subsequent increased metabolic risk. 
(A+++)
5.2 Ask for and/or screen early for gut dysmotility (gas-
trooesophageal reflux, delayed gastric emptying and 
constipation) in all children. (A+++)
Table 3 | Differential diagnosis of Silver–Russell syndrome in patients with relative microcephaly
Feature Syndrome (OMIM number)
Bloom syndrome 
(#210900)
Nijmegen 
breakage 
syndrome 
(#251260)
MOPD II (#210720) Meier–Gorlin 
syndrome (#224690, 
#61380, #613803, 
#613804, #613805)
IGF1R mutation 
or deletion 
(#147370, 
#612626)
IGF1 
mutation 
(#147440)
Birth weight 
SDS
Mean: −4.6 Mean: −1.6 Mean: −3.9 Mean: −3.8 –1.5 to −4.9 –2.5 to −4.5
Adult height 
range (cm)
• Male patients: 
128–164
• Female patients: 
115–160
• Male patients: 
161–172
• Female patients: 
150–165
Mean: 96 • Male patients: 
136–157
• Female patients: 
127–150
IGF1R mutation: 
1 female patient 
(140), 2 male 
patients (133 and 
170)
1 male 
patient: 117
Cognitive 
function
Usually normal At pre-school 
age IQ normal 
or borderline; 
progressive 
deterioration to 
moderate ID
Variable: none or 
mild ID (majority), 
occasionally severe ID
90% normal IQ, 
occasionally mild or 
moderate ID
Variable: normal 
(~50%), mild ID 
(25%), moderate or 
severe ID (25%)
Severe ID
Facial 
features
Narrow face with 
underdeveloped 
malar area and 
mandible, fairly 
prominent nose, 
sun-sensitive 
telangiectasia in 
malar distribution
Receding forehead, 
prominent 
mid-face, small 
mandible, 
up-slanting 
palpebral fissures, 
long nose and 
philtrum, large ears
Prominent, long, 
broad nose with 
hypoplastic tip, low 
insertion of columella, 
prominent eyes in 
infancy, micrognathia
Microtia, narrow, 
beaked nose with low 
insertion of columella, 
small mouth, 
retrognathia
• IGF1R mutation: 
often normal; 
triangular face, 
micrognathia.
• 15q26-qter 
deletion: 
micrognathia
No consistent 
features 
reported
Other 
features
Patchy areas of 
hypopigmented and 
hyperpigmented skin, 
feeding difficulties, 
high tumour risk 
(44% develop cancer 
by age 25 years), 
hypogonadism, type 2 
diabetes mellitus, 
immunodeficiency, 
chromosomal 
instability with 
increased frequency 
of sister chromatid 
exchange
Severe, progressive 
microcephaly, 
immunodeficiency, 
cancer 
predisposition, 
chromosomal 
instability and 
rearrangements, 
café au lait spots, 
premature ovarian 
failure
Mean OFC at birth 
−4.6 SDS, progressive 
microcephaly, 
mesomelic limb 
shortening, 
progressive 
metaphyseal 
bone dysplasia, 
hip dysplasia, 
acanthosis nigricans, 
insulin resistance, 
cryptorchidism, 
intracranial aneurysm, 
dental anomalies, 
squeaky voice
Patellar hypoplasia, 
pulmonary 
emphysema, 
cryptorchidism, 
mammary hypoplasia 
(post-pubertal 100%), 
hypoplastic labiae
• IGF1R mutation: 
pectus 
excavatum, 
5th finger 
clinodactyly, 
short fingers
• 15q26-qter 
deletion: 
fifth finger 
clinodactyly, short 
fingers, talipes, 
congenital heart 
disease, renal 
anomalies
Sensori neural 
deafness
Inheritance 
and 
molecular 
abnormality
• Autosomal 
recessive
• Mutations in 
RECQL3
• High prevalence in 
Ashkenazi Jewish 
population
• Autosomal 
recessive
• Mutations in NBN
• High prevalence 
in Slavic 
population
• Autosomal recessive
• Mutations in PCNT
• Autosomal recessive
• Mutations in ORC1, 
ORC4, ORC6, CDT1, 
CDC6
IGF1R mutation: 
majority autosomal 
dominant; 
compound 
heterozygosity 
reported in two 
patients
• Autosomal 
recessive
• Mutations 
in IGF1
ID, intellectual disability; MOPD II, microcephalic osteodysplastic primordial dwarfism type II; OFC, occipito-frontal circumference; SDS, SD score.
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5.3 Diagnose and treat any oromotor and/or sensory 
issues that affect oral intake of food. (A+++)
5.4 In patients with severe feeding failure who are 
unresponsive to standard care, anatomical or func-
tional disorders of the gastrointestinal tract, such 
as malrotation, should be excluded. (A+++)
5.5 Avoid enteral feeding by nasogastric or gastros-
tomy tube in a child capable of eating where there 
is adequate nutritional repletion. (A+++)
5.6 In cases of extreme feeding difficulties or gastrooe-
sophageal reflux, consider enteral feeding by gas-
trostomy tube (with or without fundoplication) or 
low-profile transgastric jejunostomy as a last resort to 
protect against hypoglycaemia and/or malnutrition. 
(A+++)
5.7 In the case of enteral feeding, prevent excessive 
weight gain in both volitionally and nonvolitionally 
fed children. (A++)
 *Low muscle mass makes typical BMI targets excessive in this 
population. Targets currently used in some centres include: 
Waterlow score 75–85% (REF. 88); weight-for-length SDS −2 
to −1 in first year of life; BMI target SDS between −2 to −1 
after first year of life.
Prevention of hypoglycaemia
Young children with SRS, particularly under age 5 years, 
have low muscle and liver mass, a disproportionately 
large brain-for-body size and feeding difficulties, all of 
which increase their risk of fasting hypoglycaemia and its 
potential neurocognitive consequences. The incidence of 
hypoglycaemia in these children is approximately 27%20, 
with a high frequency of spontaneous, asymptomatic 
nocturnal hypoglycaemia89.
Monitoring of levels of urinary ketones is usually 
effective in pre-empting hypoglycaemia related to fasting, 
activity or illness. This measurement can be used to deter-
mine the ‘safe fasting time’ for a child, which will change 
with age. Night time hypoglycaemia can be prevented by 
adding either high molecular weight glucose polymer (for 
infants under 10 months) or uncooked corn starch (for 
older infants and children particularly at risk) to the last 
evening feed. Dental hygiene is important as complex car-
bohydrates can promote cavities90. Severe, non-fasting and 
non-ketotic hypoglycaemia should always be identified 
and investigated further.
For episodes of preoperative fasting or febrile illness, 
intravenous glucose (10% dextrose) might be required. 
Table 4 | Differential diagnosis of Silver–Russell syndrome in patients with relative normocephaly or macrocephaly
Feature Syndrome (OMIM number)
3‑M syndrome 
(#273750)
Mulibrey nanism 
(#253250)
SHORT syndrome 
(#269880)
Floating harbour 
syndrome (#136140)
IMAGe syndrome 
(#614732)
Birth weight 
SDS
Mean: −3.1 Mean: −2.8 (range −4.0 
to 0.5)
Mean: −3.3 Mean: −2.5 –2.0 to −4.0
Adult height 
range (cm)
115–150 136–150 Mean: 154 • Female patients: 98–156
• Male patients: 106–164
• 1 male patient: 160
• 1 female patient: 
143
Cognitive 
function
Normal Mild motor and speech 
delay only
Normal Delayed speech. Intellect 
variable: normal to 
significant ID
Normal or mild ID
Facial features Anteverted nares, 
full lips, mid-face 
hypoplasia, long 
philtrum
Triangular face, frontal 
bossing
Micrognathia, high 
broad forehead, 
triangular-shaped face, 
deep-set eyes, prominent 
nose, low-set posteriorly 
rotated ears, hypoplastic 
nasal alae, facial 
lipodystrophy, thin hair
Triangular face, deep-set 
eyes, long eyelashes, 
bulbous nose, wide 
columella, short philtrum, 
thin lips
Frontal bossing, 
low-set ears, flat nasal 
bridge, short nose
Other features Prominent heels (also 
in upd(7)mat), short 
broad neck, pectus 
deformity, short thorax, 
winged scapulae, 
hyperlordosis, hip 
dysplasia, subtle 
radiographic changes 
(slender long bones, tall 
vertebral bodies)
Hepatomegaly, yellow 
spots on retina, 
progressive restrictive 
perimyocarditis, 
insulin resistance, high 
pitched voice, slender 
long bones with thick 
cortex and narrow 
medullar channels, 
shallow sella turcica, 
increased tumour risk 
(particularly Wilms 
and ovarian stromal 
tumours)
Rieger anomaly, 
dental delay, partial 
lipodystrophy, 
transparent skin, 
dimples on elbows and 
buttocks, herniae, fifth 
finger clinodactyly, 
hyperextensible joints, 
hypogonadism, high 
pitched voice, type 2 
diabetes mellitus, 
nephrocalcinosis, thin 
gracile bones
Delayed speech 
development with 
expressive language delay, 
considerably delayed bone 
age, broad fingertips
Congenital adrenal 
hypoplasia, 
metaphyseal and/or 
epiphyseal dysplasia, 
male genital 
anomalies
Inheritance 
and molecular 
abnormality
• Autosomal recessive
• Mutations in CUL7, 
OBSL1, CCDC8
• Autosomal recessive
• Mutations in TRIM37
• High prevalence in 
Finnish population
• Autosomal dominant
• Mutations in PIK3R1
• Autosomal dominant
• Mutations in SRCAP
Imprinted – 
maternally inherited 
mutations in 
CDKN1C
ID, intellectual disability, SDS, SD score.
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Children with SRS might need longer periods of gut 
rest than children with SGA but not SRS before oral 
or enteral feeding because of their gut dysmotility and 
intrinsic feeding defects. Before discharge, it is advisa-
ble to achieve an absence of ketonuria following at least 
12 h of feeding, without intravenous support. When 
hypoglycaemia remains a problem, early GH therapy 
should be considered91,92 (see following section on GH 
therapy).
6  Recommendations
6.1 Monitoring for ketonuria at home is useful to deter-
mine which children need intervention for impend-
ing hypoglycaemia. (A++)*
6.2 Develop a plan with the child’s local paediatrician 
and emergency room for rapid admission and 
intravenous dextrose treatment when the child is 
ill. (A++)
6.3 Admit children with SRS to hospital early in the 
course of an illness associated with ketonuria or 
hypoglycaemia and do not discharge them until 
they are metabolically stable and can be adequately 
fed. (A++)
6.4 Glucagon is not recommended to correct hypogly-
caemia, because of poor glycogen stores and limited 
ability for gluconeogenesis. (A+++)
6.5 Provide parents with an emergency guidance plan 
for illnesses. (A+++)
6.6 Teach parents how to recognize signs of hypogly-
caemia, measure ketones, determine the ‘safe fasting 
time’ for their child, prevent hypoglycaemia using 
complex carbohydrates and avoid fasting outside a 
controlled environment. (A+++)
6.7 In severe cases of fasting hypoglycaemia, where other 
causes have been excluded and if other alternatives 
are ineffective, consider:
• Early start of GH therapy to support glucose 
sources (increase in muscle mass and glucone-
ogenesis) (A++)
• Placement of a gastrostomy tube or jejunostomy 
tube. (A++)
 *Children with a history of hypoglycaemia who do not have 
an appropriate ketone response will require formal fasting 
studies.
Surgery and anaesthesia
Any surgery should be carefully planned due to the 
increased risk of fasting hypoglycaemia in patients with 
SRS93. As a result of their diminished weight-for-height 
ratio, low BMI and large head, young patients with SRS 
are at risk of hypothermia in a cool operating room94. 
Many children with SRS also have abnormal tooth dis-
tribution and a small mandible, which affects airway 
visualization and intubation95. Finally, young children 
with SRS who are malnourished might not heal well 
following surgery96.
7  Recommendations
7.1 Review issues related to SRS with the anaesthetist 
and surgeon in advance. (A+++)
7.2 Consider admission the night before surgery for 
early administration of intravenous dextrose before 
surgery to avoid ketonuria and hypoglycaemia. 
(A++)
7.3 Schedule first on the surgical list where possible. 
(A++)
7.4 Monitor blood glucose and administer intravenous 
dextrose during and after surgery. Do not discharge 
until ketonuria is absent and the child can sustain 
themselves on oral or enteral feeding. (A++)
7.5 Follow the intraoperative temperature maintenance 
protocol appropriate for the patient’s size, not age. 
(A+++)
7.6 Delay elective surgery until the child is adequately 
nourished. (B+)
7.7 Be aware of the high risk of malnutrition after surgery 
and follow appropriate guidelines. (A+)
Growth hormone treatment
Data on adult height in untreated patients with SRS are 
limited; however, SRS is associated with a significant 
reduction in adult height (around −3 SDS; Supplementary 
information S4 (table)) (REF. 3). SRS is an indication for 
growth-promoting GH treatment under the SGA reg-
istered licence. It is worth noting that SRS was the only 
syndrome to be included in the clinical trials of GH in 
short children born SGA that led to the US FDA and the 
European Medicines Agency (EMA) SGA indications 
for GH therapy in 2001 and 2003, respectively97–101. The 
results of these clinical trials, therefore, validate the use of 
GH for patients with SRS.
Overall, clinical trials of GH treatment in patients with 
SGA (in which patients with SRS were included) demon-
strated a satisfactory growth response and an increase 
in predicted adult height of 7–11 cm at pharmacological 
doses of GH97–100,102. However, the response in patients with 
SRS was not investigated until a Dutch longitudinal study 
analysed the response to GH in 62 children with a clinical 
diagnosis of SRS using the NH-CSS compared with 227 
short, non-syndromic children born SGA. Overall, the 
study showed a similar response to GH in patients with 
SRS compared with non-SRS children born SGA (mean 
total height gains of 1.30 SDS and 1.26 SDS, respectively); 
however, the final adult height attained in patients with 
SRS was lower (mean adult height −2.17 SDS versus 
−1.65 SDS for non-SRS children born SGA)87. Although 
the mean height at the start of GH treatment in patients 
with SRS was statistically significantly lower than in those 
without SRS, it was shown that patients with all SRS sub-
types benefited from GH treatment, with a trend towards 
increased height gain in patients with upd(7)mat or clini-
cal SRS. In addition, some interim100,102 and long-term103,104 
studies have focused on the response to GH specifically in 
patients with SRS, albeit without a control group of non-
SRS short children born SGA. Strong predictors of the 
short-term and long-term responses to GH were age and 
height SDS at the start of GH treatment (both inversely 
related)103–105. However, the study by Rakover et al.105 of 33 
patients with SRS lacked data on adult height. Mean total 
height gain ranged from +1.2 to +1.4 SDS for GH doses of 
35–70 μg/kg per day, which is similar to that achieved in 
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patients with non-syndromic SGA97,103,104. In 2007, an SGA 
consensus statement advocated early treatment with GH 
for children born SGA, including those with SRS, who had 
severe growth retardation (height SDS ≤2.5; age 2–4 years; 
dose 35–70 μg/kg per day)106.
Additional potential benefits of GH treatment are 
increases in appetite, lean body mass and muscle power, 
which can result in improved mobility86,107. In patients 
with Prader–Willi syndrome, another imprinting disor-
der, GH treatment started in infancy results in increased 
lean body mass and motor development, as well as 
decreased fat mass108,109; consequently, GH treatment 
is now recommended from infancy in this condition. 
Children with SRS who are <2 years old typically present 
with low muscle mass and hypotonia, similarly to patients 
with Prader–Willi syndrome15, and could also benefit 
from early GH treatment. Further studies are necessary 
to investigate this option in patients with SRS.
Classic GH deficiency is neither a common nor a 
relevant cause of short stature in SRS, nor is it predic-
tive of the response to GH treatment in children born 
SGA103,105,110. Furthermore, given the risk of hypogly-
caemia associated with fasting required for GH testing, 
testing children with SRS might carry added risks.
For most children with SRS, an increase in height 
velocity of ≥3 cm per year is the lower limit of an effective 
response range106. The growth response depends on the 
patient’s age, GH dose, height deficit, rate of weight gain 
and confounding problems such as intercurrent illness 
and scoliosis.
Levels of insulin-like growth factor 1 (IGF1) in 
response to GH treatment in patients with SRS are dif-
ficult to interpret. Children with 11p15 LOM have sig-
nificantly higher IGF1 levels than children with upd(7)
mat and other children born SGA, which suggests an ele-
ment of IGF1 resistance in patients with 11p15 LOM73,111. 
Basal serum levels of IGF1 in the upper quartile of the 
normal age-related range or higher can be expected in 
children with SRS, especially those with 11p15 LOM73. 
In children with 11p15 LOM, serum levels of insulin-like 
growth factor-binding protein 3 (IGFBP3) are also ele-
vated111. IGF1 levels might rise significantly above the 
reference range in children with SRS on standard doses 
of GH87,111. Further studies are needed to understand how 
best to use IGF1 and IGFBP3 serum levels to monitor GH 
doses in children with SRS and IGF1 resistance.
Comprehensive reviews on the use of GH in children 
born SGA have concluded that GH treatment seems to 
be safe and effective112. Adverse effects due to GH treat-
ment are no more frequent in children with SRS than 
in those with non-syndromic SGA87,113 and no specific 
precautions are advised.
8  Recommendations
8.1 Defer GH treatment until caloric deficits are 
addressed. (A++)
8.2 Avoid GH stimulation testing. (A++)
8.3 Goals of GH treatment are to improve body com-
position (especially lean body mass), psychomotor 
development and appetite, to reduce the risk of 
hypoglycaemia, and to optimise linear growth. (A++)
8.4 Treat with GH as soon as possible; starting at age 
2–4 years is adequate for the majority of patients; 
however, due consideration should be given to the 
exceptions listed below*. (A++)
8.5 Start GH at a dose of approximately 35 μg/kg per 
day. Use the lowest dose that results in catch-up 
growth. (A+++)
8.6 Terminate GH therapy when height velocity is 
<2 cm per year over a 6-month period and bone age 
is >14 years (female patients) or >17 years (male 
patients). (A++)
8.7 If response to GH is poor, re-evaluate the underlying 
diagnosis, GH dose, IGF1 response, adherence to 
therapy and other confounding systemic problems. 
(A+++)
8.8 Monitor circulating levels of IGF1 and IGFBP3 at 
least yearly during GH treatment. (A++)
 *GH treatment does not have a specific indication for 
SRS and is prescribed under the SGA indication (height 
SDS –2.5; age >2–4 years; dose 35–70 μg/kg per day)106. 
Exemptions from the current SGA licensed indication used 
in some centres include starting GH therapy below the age 
of 2 years in case of: severe fasting hypoglycaemia; severe 
malnutrition, despite nutritional support, which will lead to 
gastrostomy if no improvement is seen; and severe muscular 
hypotonia.
Bone age advancement and puberty
The published literature on the natural history of bone 
age progression in patients with SRS is limited. Early 
bone age delay is followed by rapid advancement typ-
ically at around 8–9 years of age3,81,113 but sometimes 
much younger, especially in nonvolitionally overfed 
children. Onset of puberty is usually within the normal 
range (8–13 years in girls and 9–14 years in boys)114 but 
at the younger end of the spectrum3,73,87,115. Adrenarche 
can be early and aggressive in comparison with children 
born with non-SRS SGA, particularly in those with 
11p15 LOM116.
Our experience is that in patients with SRS and early 
adrenarche, the onset of central puberty might be ear-
lier and the tempo faster than expected. In the past few 
decades, population studies analysing the timing of 
normal puberty observed a mean age of puberty onset 
of 9.7–10.0 years in girls114. As a group, girls with SRS 
seem to start central puberty at a mean age of 9.1 years 
(I. Netchine, unpublished work). This early puberty 
further accelerates bone age maturation, which leads 
to an attenuated pubertal growth spurt and compro-
mised adult height. Children with upd(7)mat are likely 
to progress to central puberty at an even younger age 
than patients with SRS and 11p15 LOM (mean starting 
age 8.5 years in girls and 9.5 years in boys) (I. Netchine, 
unpublished work). A rapid increase in BMI might also 
exacerbate the tendency to early adrenarche and central 
puberty117–119.
The window for effective GH treatment seems 
to be shorter in patients with SRS than in non-SRS 
patients with SGA. In a study comparing a cohort 
of patients with SRS and a cohort of patients born 
SGA but without SRS, puberty started significantly 
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earlier in the former (at 10.2 years versus 11.2 years 
in girls with SRS and non-SRS SGA, respectively, and 
at 11.4 years versus 12.0 years in boys with SRS and 
non-SRS SGA, respectively)87. Furthermore, a steeper 
decline in height SDS from the onset of puberty until 
adult height was seen in patients with SRS, which 
contributed to a lower adult height and a larger dis-
tance to target height than in non-SRS patients with 
SGA. However, in 17 patients with SRS in this study, 
puberty was postponed for 2 years with gonadotro-
pin-releasing hormone analogue (GnRHa) due to a 
low predicted adult height. The effect of GnRHa on 
final height has been analysed in a cohort of patients 
with SGA, including patients with SRS120,121. This anal-
ysis suggested that the combination of GnRHa, started 
at the initiation of puberty and continued for at least 
2 years, along with GH treatment, improves adult 
height in patients born SGA with a poor adult height 
prognosis. A retrospective study of GnRHa treatment 
specifically in patients with SRS did not detect an 
effect of GnRHa on adult height, but this therapy was 
used in only 16 of 37 patients and was not standard-
ized104. Further studies are required to specifically look 
at its effects in patients with SRS.
Aromatase catalyses the rate-limiting step in the 
conversion of androstenedione to oestrone and tes-
tosterone to oestradiol. In patients with adrenarche 
with advancing bone age, but without central puberty, 
third-generation aromatase inhibitors (such as anas-
trozole) might be helpful in preventing rapid bone 
maturation, but are currently not licensed for growth 
disorders122. An 18-month double-blind clinical trial is 
currently underway to study the efficacy and tolerance 
of treatment with anastrozole to slow bone maturation 
related to pathological adrenarche in patients with SRS 
and Prader–Willi syndrome123.
9  Recommendations
9.1 Monitor for signs of premature adrenarche, fairly 
early and accelerated central puberty, and insulin 
resistance. (A+++)
9.2 Monitor and anticipate acceleration of bone age 
especially from mid childhood. (A++)
9.3 Consider personalized treatment with GnRHa for 
at least 2 years in children with evidence of central 
puberty (starting no later than age 12 years in girls 
and age 13 years in boys) to preserve adult height 
potential. (A++)
Long-term metabolic complications
Individuals born with a low birth weight are at increased 
risk of adult health problems including coronary heart 
disease124–126, hypertension, dyslipidaemia, insulin resist-
ance and obesity (the metabolic syndrome)127–130. Studies 
of children born SGA indicate that those who have rapid 
or disproportionate catch-up in weight are at particularly 
high risk119,131,132.
Insulin resistance in young, pre-pubertal, children 
with SRS can be atypical and difficult to detect in the 
fasting state; however, impaired glucose tolerance can be 
confirmed on formal oral glucose tolerance testing133,134. 
Insulin resistance becomes more classic in the pubertal 
or post-pubertal age groups with elevation in fasting lev-
els of glucose and insulin, and possibly the development 
of type 2 diabetes mellitus135,136.
Overall, GH therapy seems to have positive meta-
bolic effects in children born SGA137, but specific data 
on such effects in SRS are lacking. Many studies of long-
term GH treatment in children born SGA have shown 
positive outcomes, including increased lean body mass, 
reduced fat mass, decreased blood pressure and an 
improved lipid profile107,120,137,138, which might last after 
discontinuation of therapy138,139.
In a study of 110 children born SGA treated with GH, 
those with the highest baseline levels of IGF1 were the 
least insulin sensitive. Gains in height and IGF1 response 
were positively associated with insulin secretion140. In 
SRS, children with 11p15 LOM seem to be at a higher 
metabolic risk than children who have upd(7)mat and 
other children born SGA due to poor muscle mass and 
raised levels of IGF1 (REFS 15,16,73,87). Further research 
is, therefore, required on the long-term effects of GH 
therapy on body composition and metabolic parameters 
in SRS and its various genotypes.
10  Recommendations
10.1 Avoid excessive or rapid weight gain to prevent 
increased insulin resistance, which is associated with 
early and rapidly advancing adrenarche, early cen-
tral puberty, and, in girls, a future risk of developing 
polycystic ovary syndrome. (A++)
10.2 Raise awareness among gastroenterologists, dieti-
cians, neonatologists, paediatricians and primary 
health-care providers of the importance of not 
overfeeding this group of children. (A+++)
10.3 Advise parents, grandparents and care-givers 
about the risk of insulin resistance associated with 
intrauterine growth retardation and overfeeding. 
(A+++)
10.4 Screen for physical and biochemical indicators of 
insulin resistance during GH treatment, especially 
in children with low muscle mass and high baseline 
levels of IGF1. (A+)
10.5 In patients with clinical signs of insulin resistance, 
consider formal assessment of insulin sensitivity 
with a 2-h oral glucose tolerance test including 
measurement of insulin and C-peptide levels (A++)
10.6 Advocate a healthy diet and lifestyle in older chil-
dren and young adults with particular emphasis 
on protein calorie balance and regular exercise to 
avoid disproportionate weight gain, particularly 
after discontinuation of GH treatment. (A+++)
Neurocognitive problems
Motor and speech delay are common in children with 
SRS4,16–18,20 (TABLE 2). Motor delay might be related to 
reduced muscle bulk and fairly large head size. Verbal 
dyspraxia and more global developmental delay or learn-
ing difficulties, usually mild, have been described in 
some children with SRS, particularly those with upd(7)
mat12,15,16,20,141. Autistic spectrum disorder has also been 
reported more frequently in this subgroup than in 
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the other subgroups of SRS15. Myoclonus dystonia in 
patients with upd(7)mat is probably associated with 
altered expression of the paternally expressed SGCE on 
chromosome 7q21 (REFS 20,40,142,143).
11  Recommendations
11.1 Refer infants and children with SRS for a devel-
opmental assessment when necessary to ensure 
appropriate intervention as early as possible. 
(A+++)
11.2 In patients with upd(7)mat, check for symptoms 
of myoclonus dystonia at each clinical appoint-
ment and refer early to a paediatric neurologist if 
required. (A+++)
11.3 Monitor children with upd(7)mat for signs of ver-
bal or oromotor dyspraxia and/or signs of autistic 
spectrum disorders. (A+++)
11.4 Inform parents about increased risk of speech, oro-
motor and learning disabilities (especially in those 
with upd(7)mat). (A+++)
11.5 Follow up school-age children for any learning dif-
ficulties, psychosocial challenges and/or cognitive 
delay, to enable appropriate intervention. (A+++)
Orthopaedic problems
Orthopaedic problems seen in association with SRS 
include limb or body asymmetry, scoliosis, hip dysplasia 
and hand and/or foot anomalies (TABLE 2).
Limb asymmetry can affect the arms, legs or both. In 
seven patients with clinically diagnosed SRS, limb length 
discrepancy was not significantly affected by GH treat-
ment144. Limb lengthening surgery performed to equal-
ize limb lengths in patients with SRS has shown positive 
results145.
Scoliosis has been reported in 9–36% of individuals 
with SRS20,146,147. The causal relationship to leg length 
asymmetry is not clear146,147. Associated back pain has 
been reported inconsistently5,146. GH therapy might be 
associated with worsening of existing scoliosis; how-
ever, causality has not been established148. A study in a 
large group of children with Prader–Willi syndrome (an 
imprinting disorder with clinical features that overlap 
with those of SRS: growth failure; infant hypotonia; early 
feeding difficulties; and an increased risk of scoliosis) 
has clearly shown that GH therapy does not influence 
onset and progression of scoliosis149; however, specific 
studies are required to determine whether GH therapy 
modifies the risk of scoliosis in patients with SRS.
12  Recommendations
12.1 Where necessary, refer to a paediatric orthopaedic 
surgeon for collaborative management of body 
asymmetry, limb length discrepancy and scoliosis. 
(A+++)
12.2 Routinely examine all patients with SRS for scoli-
osis. (A+++)
12.3 Before initiation of GH therapy, refer patients with 
scoliosis to the orthopaedic team and monitor 
while receiving GH. (A+++)
12.4 Evaluate leg length asymmetry regularly and con-
sider orthopaedic management if necessary. (A++)
Maxillofacial abnormalities
SRS is characterized by craniofacial disproportion, 
which results in a triangular-shaped face95. Delayed den-
tal eruption, microdontia, absence of secondary teeth 
and blunted condyles have all been reported in patients 
with SRS150–152.
In our experience, the upper jaw arch is frequently 
narrow and crowded, but crowding might be severe in 
the lower arch, with displacement of lower incisors into 
a lingual position. Micrognathia is frequent, with lack 
of mandibular growth, which results in a small, pointed 
chin and an overbite. Children with notable facial 
asymmetry might have a crossbite that impairs normal 
chewing. Velopharyngeal insufficiency with or without a 
submucous cleft is quite common in patients with 11p15 
LOM SRS20. Otitis media is frequent in young children 
with SRS7 and seems to be improved by orthodontic 
treatment20.
Orthodontic intervention in children with SRS 
can help normalize oropharangeal function and facial 
appearance. An experienced craniofacial team, including 
orthodontists, plastic surgeons and ear, nose and throat 
surgeons is ideal. Multiple orthodontic techniques have 
been used successfully153. Currently, rapid palatal expan-
sion is the most effective technique to change the shape 
of the face154.
Many patients with SRS report excessive daytime 
fatigue, snoring and/or disrupted sleep. However, data 
are very limited regarding sleep problems, including 
sleep disordered breathing, in association with SRS. 
A retrospective study identified mild sleep disordered 
breathing in 74% of patients with SRS (not exacerbated 
with GH therapy)155. Further studies are necessary.
13  Recommendations
13.1 Develop a referral relationship with a maxillofacial 
team or orthodontist who has experience caring 
for patients with SRS. (A++)
13.2 Refer patients to the maxillofacial team for assess-
ment after eruption of primary dentition when 
necessary. (A++)
13.3 Encourage early orthodontic intervention and 
compliance with follow-up. (A+)
13.4 Screen for symptoms of sleep disordered breath-
ing (such as snoring, apnoeas, excessive daytime 
fatigue, disrupted sleep and agitation). (A++)
13.5 Refer patients with suspected sleep disordered 
breathing to the appropriate specialist for evaluation 
of obstructive sleep apnoea. (A++)
Other congenital anomalies
Congenital anomalies have been described in a minor-
ity of patients with SRS, particularly those with 11p15 
LOM (see Supplementary information  S1 (table)). 
Genital abnormalities, including cryptorchidism and 
hypospadias, occur frequently in boys16,20. Mayer–
Rokitansky–Kuster–Hauser syndrome in female patients 
is characterized by congenital hypoplasia or aplasia of the 
uterus and upper part of the vagina16,18,156,157. Structural 
renal anomalies18,20 and congenital heart defects4,18,20,158 
have also been reported.
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14  Recommendations
14.1 Investigate genital abnormalities in boys. (A+++)
14.2 Investigate girls with primary amenorrhoea for 
Mayer–Rokitansky–Kuster–Hauser syndrome. 
(A+++)
Adulthood
Very little information exists in the literature regarding 
the long-term natural history of SRS. The majority of 
individuals with SRS are not routinely followed up, and 
the small numbers of adults reported have few medical 
problems. However, it is well recognized that being SGA 
at birth with accelerated gain in weight for length, par-
ticularly during early life, increases the risk of metabolic 
problems in adulthood119,132,159 (see previous discussion). 
Medical problems reported in adult patients with 11p15 
LOM include hypertension, dilated cardiomyopathy, 
type 2 diabetes mellitus, hypercholesterolaemia, fatty 
liver infiltration, elevated glucose levels and raised 
HbA1c levels135,136,160; however, these reports might not 
be representative of the population as a whole.
15  Recommendations
15.1 Consider medical follow-up of adolescents and 
young adult patients with SRS or develop collab-
oration with a general or internal medicine team 
for follow-up. (A+++)
15.2 Avoid losing contact with adult patients with SRS, 
to facilitate their participation in, and potential 
benefit from, future clinical research. (A+++)
Genetic counselling
Accurate genetic counselling depends on the underlying 
molecular cause. 11p15 LOM is associated with a low 
recurrence risk (with parents of a child with SRS being 
unlikely to have another affected child). The offspring risk 
is also low (meaning that individuals with SRS are unlikely 
to pass the condition on to their children). However, 
empirical figures are not available. Only three sibships 
with 11p15 LOM are reported in the literature13,20, and 
the underlying mechanism is unknown in all three.
The potential for a familial trans-acting gene muta-
tion suggests that the recurrence risk in patients with 
SRS and MLID could be higher than in other patients 
with SRS; however, evidence to support this supposition 
does not yet exist.
Rare familial cases of SRS have been reported with 
underlying mechanisms including: maternally inherited 
11p15 duplication24,26 (see Supplementary information S2 
(table)); maternally inherited CDKN1C gain-of-function 
mutations60; and paternally inherited IGF2 loss-of-func-
tion mutations61. In these families, the risk of recurrence 
might be as high as 50%24,26,60,61. Investigation for under-
lying CNVs in patients with 11p15 LOM is, therefore, 
important. upd(7)mat is associated with a low recurrence 
and offspring risk (if the karyotype of the patient is nor-
mal)50. Data are limited regarding the risk of parents of 
children with clinically diagnosed SRS having another 
child with SRS; however, the overall risk is probably low. 
Similarly, the offspring risk for individuals with clinically 
diagnosed SRS is likely to be low.
Table 5 | Checklist for management of patients with Silver–Russell syndrome
Management issue At 
diagnosis
0–2 
years
2–10 
years
10–18 
years
General
Document molecular subtype R N/A N/A N/A
Provide support group information R N/A N/A N/A
Genetic counselling for parents R N/A N/A N/A
Feeding and growth
Exclude feeding difficulties R R C C
Ensure nutritional repletion R R R R
Screen for gut dysmotility R R C C
Screen for oromotor or sensory issues R C C C
Avoid rapid postnatal and/or 
childhood weight gain
R R R R
Measure head circumference R R R R
Measure and monitor linear growth R R R R
Calculate and monitor BMI R R R R
Screen for symptoms and/or signs of 
hypoglycaemia
R R C C
Consider growth hormone treatment R C R R
Monitor IGF1 or IGFBP3 levels (more 
than yearly)
R C R R
Monitor clinically (with or without 
biochemical testing) for insulin 
resistance
R N/A R R
Adrenarche and puberty
Monitor clinically for early 
adrenarche
R R R N/A
Anticipate early bone age 
advancement
R N/A R R
Consider treatment of early or rapid 
central puberty
R N/A R C
Other medical issues
Monitor for symptoms of sleep 
disordered breathing
R R R R
Orthodontic or dental R C R R
Ear, nose and throat R C C C
Neurodevelopment
Developmental assessment R R C C
Screen for myoclonus dystonia* R R R R
Speech and language evaluation R R R C
School progress R N/A C C
Monitor for speech, motor and 
cognitive difficulties
R C R C
Psychosocial evaluation R N/A C C
Musculoskeletal
Limb length discrepancy or 
asymmetry
R C C C
Scoliosis R C C C
Screen for hip dysplasia R R C C
*upd(7)mat only. C, consider assessment, depending on the clinical features of the patient; 
N/A, not applicable; R, recommend assessment (unless N/A to age group).
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16  Recommendation
16.1 Genetic counselling should be performed by 
a health professional experienced in the field 
of imprinting disorders. As the recurrence risk 
associated with CNVs is dependent on their size, 
location and parental origin, these should be 
taken into consideration during counselling for 
the family. (A+++)
Conclusions
Children with SRS and their families face challenges 
from birth to adulthood. In addition to the problems 
associated with being born SGA, clinicians treating 
patients with SRS need to be aware of syndrome-spe-
cific management issues. These include substantial 
feeding difficulties, severe postnatal growth failure 
with no catch-up, recurrent hypoglycaemia, premature 
adrenarche, fairly early and rapid puberty, insulin resist-
ance, body asymmetry, orthodontic issues, sleep disor-
dered breathing and the potential for other congenital 
anomalies.
Presented here are the first international consensus 
guidelines for the diagnosis and management of SRS, 
based on published evidence and expert opinion. A sum-
mary of all 72 recommendations, including a flow chart 
for the investigation and diagnosis of SRS, is available as 
supplementary information online (see Supplementary 
information S5).
These management recommendations apply to all 
patients clinically diagnosed with SRS, both with and 
without a molecularly confirmed diagnosis. However, 
identification of the underlying molecular subtype 
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